niacinamide has been researched along with Recrudescence in 66 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial." | 9.19 | Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014) |
| "Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12." | 9.15 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011) |
| "We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib." | 8.90 | [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy]. ( Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014) |
| "The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT)." | 8.89 | Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. ( Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013) |
| "Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence." | 7.83 | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016) |
| "Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC)." | 7.81 | [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H, 2015) |
| "We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy." | 7.79 | [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. ( Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H, 2013) |
| "There are scarce data on the use of sorafenib for the treatment of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT)." | 7.78 | Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012) |
| "The role of sorafenib is unclear in multimodal treatment for hepatocellular carcinoma (HCC)." | 7.77 | [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. ( Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H, 2011) |
| "Our study demonstrates the safety and potential benefit of sorafenib in reducing the incidence of hepatocellular carcinoma recurrence and in extending disease-free and overall survival for high-risk liver transplant recipients." | 7.76 | Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010) |
| "To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid." | 7.70 | Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. ( Goon, AT; Khoo, LS; Tan, SH; Tan, T, 2000) |
| "A 60-year-old woman with recurrent papular and vesiculobullous lesions of erythema elevatum diutinum responded to treatment with 100 mg of oral niacinamide three times a day and 250 mg of tetracycline hydrochloride four times a day." | 7.66 | Erythema elevatum diutinum treated with niacinamide and tetracycline. ( Kohler, IK; Lorincz, AL, 1980) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Adult glioblastoma patients at any recurrence after standard temozolomide chemoradiotherapy received sorafenib (400 mg twice daily) and continuous daily temozolomide (50 mg/m²/day)." | 6.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Metastatic neuroblastoma is an aggressive malignancy with a poor prognosis." | 5.43 | Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases. ( Fujisaki, H; Hara, J; Nakano, Y; Nitani, C; Okada, K; Yamasaki, K, 2016) |
| "Sorafenib treatment was initiated." | 5.42 | [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015) |
| "The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al." | 5.38 | Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. ( Cooper, T; Watt, TC, 2012) |
| " Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%." | 5.38 | High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012) |
| "This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial." | 5.19 | Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014) |
| "Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12." | 5.15 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011) |
| "We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib." | 4.90 | [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy]. ( Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014) |
| "The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT)." | 4.89 | Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. ( Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013) |
| "Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence." | 3.83 | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016) |
| "Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC)." | 3.81 | [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H, 2015) |
| "We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy." | 3.79 | [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. ( Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H, 2013) |
| " NanoHHI potently suppressed in vivo tumor growth of HCC xenografts in both subcutaneous and orthotopic milieus, and in contrast to sorafenib, resulted in significant attenuation of systemic metastases in the orthotopic setting." | 3.78 | Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. ( Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF, 2012) |
| "There are scarce data on the use of sorafenib for the treatment of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT)." | 3.78 | Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012) |
| "The role of sorafenib is unclear in multimodal treatment for hepatocellular carcinoma (HCC)." | 3.77 | [The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. ( Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H, 2011) |
| "Our study demonstrates the safety and potential benefit of sorafenib in reducing the incidence of hepatocellular carcinoma recurrence and in extending disease-free and overall survival for high-risk liver transplant recipients." | 3.76 | Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010) |
| "To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid." | 3.70 | Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. ( Goon, AT; Khoo, LS; Tan, SH; Tan, T, 2000) |
| "A 60-year-old woman with recurrent papular and vesiculobullous lesions of erythema elevatum diutinum responded to treatment with 100 mg of oral niacinamide three times a day and 250 mg of tetracycline hydrochloride four times a day." | 3.66 | Erythema elevatum diutinum treated with niacinamide and tetracycline. ( Kohler, IK; Lorincz, AL, 1980) |
| "Patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations (FLT3-ITD+) who relapse after allogeneic transplantation (allo-SCT) have a very dismal prognosis with the currently available treatment options." | 2.84 | Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. ( Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T, 2017) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Sorafenib dose was escalated from 90 to 110 mg/m(2) twice daily with fixed doses of bevacizumab at 5 mg/kg every 3 weeks and cyclophosphamide at 50 mg/m(2) daily." | 2.78 | Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ( Baker, SD; Billups, CA; Davidoff, AM; Fofana, D; Furman, WL; Hu, S; Leung, W; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Reddick, WE; Santana, VM; Spunt, SL; Stewart, CF; Turner, D; Wu, J, 2013) |
| "Adult glioblastoma patients at any recurrence after standard temozolomide chemoradiotherapy received sorafenib (400 mg twice daily) and continuous daily temozolomide (50 mg/m²/day)." | 2.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Pemphigus is a rare autoimmune bullous disorder." | 2.47 | [Pemphigus: a review]. ( Joly, P; Sin, C, 2011) |
| "Hepatocellular carcinoma is dramatically increasing in incidence that is mostly attributed to chronic hepatitis C and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and its clinical phenotype diabetes and obesity." | 2.46 | Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010) |
| "In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients without maintenance." | 1.72 | Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia. ( Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F, 2022) |
| "We studied three FLT3 ITD acute myeloid leukemia (AML) patients who relapsed after allogeneic haematopoietic stem cell transplantation (alloHSCT) and received multikinase inhibitor (MKI) sorafenib as part of salvage therapy." | 1.48 | The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. ( Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A, 2018) |
| "To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT)." | 1.48 | [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation]. ( Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X, 2018) |
| "Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT." | 1.46 | Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. ( Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E, 2017) |
| "Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency." | 1.43 | [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia]. ( DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016) |
| "Metastatic neuroblastoma is an aggressive malignancy with a poor prognosis." | 1.43 | Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases. ( Fujisaki, H; Hara, J; Nakano, Y; Nitani, C; Okada, K; Yamasaki, K, 2016) |
| "Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission, and sorafenib monotherapy as mauntenance treatment after complete remission (CR)." | 1.43 | [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation]. ( Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y, 2016) |
| "Sorafenib treatment was initiated." | 1.42 | [A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015) |
| "The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al." | 1.38 | Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. ( Cooper, T; Watt, TC, 2012) |
| " Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%." | 1.38 | High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012) |
| "Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus." | 1.38 | Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. ( Luyken, J; Neuhaus, T, 2012) |
| "Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT)." | 1.37 | Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. ( Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M, 2011) |
| "Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway." | 1.37 | Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. ( Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F, 2011) |
| "We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen." | 1.36 | A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. ( Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.55) | 18.7374 |
| 1990's | 2 (3.03) | 18.2507 |
| 2000's | 4 (6.06) | 29.6817 |
| 2010's | 53 (80.30) | 24.3611 |
| 2020's | 4 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Aydin, S | 1 |
| Passera, R | 1 |
| Scaldaferri, M | 1 |
| Dellacasa, CM | 1 |
| Poggiu, M | 1 |
| Cattel, F | 1 |
| Zallio, F | 1 |
| Brunello, L | 1 |
| Giaccone, L | 1 |
| Dogliotti, I | 1 |
| Busca, A | 1 |
| Witkowska-Patena, E | 1 |
| Giżewska, A | 1 |
| Dziuk, M | 1 |
| Miśko, J | 1 |
| Budzyńska, A | 1 |
| Walęcka-Mazur, A | 1 |
| Witt, EA | 1 |
| Reissner, KJ | 1 |
| Goto, H | 1 |
| Kitagawa, N | 1 |
| Sekiguchi, H | 1 |
| Miyagi, Y | 1 |
| Keino, D | 1 |
| Sugiyama, M | 1 |
| Sarashina, T | 1 |
| Miyagawa, N | 1 |
| Yokosuka, T | 1 |
| Hamanoue, S | 1 |
| Iwasaki, F | 1 |
| Shiomi, M | 1 |
| Goto, S | 1 |
| Tanaka, Y | 1 |
| Metzelder, SK | 1 |
| Schroeder, T | 2 |
| Lübbert, M | 1 |
| Ditschkowski, M | 1 |
| Götze, K | 1 |
| Scholl, S | 1 |
| Meyer, RG | 1 |
| Dreger, P | 1 |
| Basara, N | 1 |
| Fey, MF | 1 |
| Salih, HR | 1 |
| Finck, A | 1 |
| Pabst, T | 1 |
| Giagounidis, A | 2 |
| Kobbe, G | 2 |
| Wollmer, E | 1 |
| Finke, J | 1 |
| Neubauer, A | 2 |
| Burchert, A | 2 |
| Lange, A | 1 |
| Jaskula, E | 1 |
| Lange, J | 1 |
| Dworacki, G | 1 |
| Nowak, D | 1 |
| Simiczyjew, A | 1 |
| Mordak-Domagala, M | 1 |
| Sedzimirska, M | 1 |
| Xuan, L | 2 |
| Fan, ZP | 1 |
| Zhang, Y | 2 |
| Xu, N | 2 |
| Ye, JY | 1 |
| Zhou, X | 1 |
| Wang, ZX | 1 |
| Sun, J | 2 |
| Liu, QF | 1 |
| Huang, F | 2 |
| Marafi, F | 1 |
| Sasikumar, A | 1 |
| Fathallah, W | 1 |
| Esmail, A | 1 |
| Xicoy, B | 1 |
| Zamora, L | 1 |
| Yordanova, A | 1 |
| Hose, D | 1 |
| Neben, K | 1 |
| Witzens-Harig, M | 1 |
| Gütgemann, I | 1 |
| Raab, MS | 1 |
| Moehler, T | 1 |
| Goldschmidt, H | 1 |
| Schmidt-Wolf, IG | 1 |
| Zustovich, F | 1 |
| Landi, L | 1 |
| Lombardi, G | 2 |
| Porta, C | 1 |
| Galli, L | 1 |
| Fontana, A | 1 |
| Amoroso, D | 1 |
| Galli, C | 1 |
| Andreuccetti, M | 1 |
| Falcone, A | 1 |
| Zagonel, V | 1 |
| Legault, G | 1 |
| Kieran, MW | 1 |
| Scott, RM | 1 |
| Chordas, C | 1 |
| Milla, SS | 1 |
| Karajannis, MA | 1 |
| Komatsu, H | 1 |
| Tsukamoto, T | 1 |
| Kodai, S | 1 |
| Kanazawa, A | 1 |
| Shimizu, S | 1 |
| Yamazoe, S | 1 |
| Ohira, G | 1 |
| Nakajima, T | 1 |
| Nakai, T | 1 |
| Kawasaki, Y | 1 |
| Kioka, K | 1 |
| Mukai, R | 1 |
| Wada, H | 1 |
| Tomimaru, Y | 1 |
| Hama, N | 1 |
| Kawamoto, K | 1 |
| Kobayashi, S | 1 |
| Eguchi, H | 1 |
| Umeshita, K | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Nagano, H | 1 |
| Perova, T | 1 |
| Grandal, I | 1 |
| Nutter, LM | 1 |
| Papp, E | 1 |
| Matei, IR | 1 |
| Beyene, J | 1 |
| Kowalski, PE | 1 |
| Hitzler, JK | 1 |
| Minden, MD | 1 |
| Guidos, CJ | 1 |
| Danska, JS | 1 |
| Liegel, J | 1 |
| Courville, E | 1 |
| Sachs, Z | 1 |
| Ustun, C | 1 |
| Guidetti, A | 1 |
| Carlo-Stella, C | 1 |
| Locatelli, SL | 1 |
| Malorni, W | 1 |
| Mortarini, R | 1 |
| Viviani, S | 1 |
| Russo, D | 1 |
| Marchianò, A | 1 |
| Sorasio, R | 1 |
| Dodero, A | 1 |
| Farina, L | 1 |
| Giordano, L | 1 |
| Di Nicola, M | 1 |
| Anichini, A | 1 |
| Corradini, P | 1 |
| Gianni, AM | 1 |
| Bruedigam, C | 1 |
| Bagger, FO | 1 |
| Heidel, FH | 1 |
| Paine Kuhn, C | 1 |
| Guignes, S | 1 |
| Song, A | 1 |
| Austin, R | 1 |
| Vu, T | 1 |
| Lee, E | 1 |
| Riyat, S | 1 |
| Moore, AS | 1 |
| Lock, RB | 1 |
| Bullinger, L | 1 |
| Hill, GR | 1 |
| Armstrong, SA | 1 |
| Williams, DA | 1 |
| Lane, SW | 1 |
| Lara, PN | 1 |
| Moon, J | 1 |
| Redman, MW | 1 |
| Semrad, TJ | 1 |
| Kelly, K | 1 |
| Allen, JW | 1 |
| Gitlitz, BJ | 1 |
| Mack, PC | 1 |
| Gandara, DR | 1 |
| Gilbert, J | 1 |
| Schell, MJ | 1 |
| Zhao, X | 1 |
| Murphy, B | 1 |
| Tanvetyanon, T | 1 |
| Leon, ME | 1 |
| Neil Hayes, D | 1 |
| Haigentz, M | 1 |
| Saba, N | 1 |
| Nieva, J | 1 |
| Bishop, J | 1 |
| Sidransky, D | 1 |
| Ravi, R | 1 |
| Bedi, A | 1 |
| Chung, CH | 1 |
| Watanabe, Y | 1 |
| Nakaba, H | 1 |
| Taniguchi, E | 1 |
| Kikkawa, H | 1 |
| Tamagawa, H | 1 |
| Sasaki, M | 1 |
| Kitayama, T | 1 |
| Doi, Y | 1 |
| Oguchi, Y | 1 |
| Giri, S | 1 |
| Hamdeh, S | 1 |
| Bhatt, VR | 1 |
| Schwarz, JK | 1 |
| Badar, T | 1 |
| Kantarjian, HM | 1 |
| Nogueras-Gonzalez, GM | 1 |
| Borthakur, G | 1 |
| Garcia Manero, G | 1 |
| Andreeff, M | 2 |
| Konopleva, M | 2 |
| Kadia, TM | 1 |
| Daver, N | 1 |
| Wierda, WG | 1 |
| Luthra, R | 1 |
| Patel, K | 1 |
| Oran, B | 1 |
| Champlin, R | 1 |
| Ravandi, F | 3 |
| Cortes, JE | 1 |
| Nakagawa, T | 1 |
| Chubachi, S | 1 |
| Gon, H | 1 |
| Kido, M | 1 |
| Fukumoto, T | 1 |
| Takebe, A | 1 |
| Tanaka, M | 1 |
| Kuramitsu, K | 1 |
| Kinoshita, H | 1 |
| Fukushima, K | 1 |
| Urade, T | 1 |
| So, S | 1 |
| Shinzeki, M | 1 |
| Matsumoto, I | 1 |
| Ajiki, T | 1 |
| Ku, Y | 1 |
| Röllig, C | 1 |
| Serve, H | 1 |
| Hüttmann, A | 1 |
| Noppeney, R | 1 |
| Müller-Tidow, C | 1 |
| Krug, U | 1 |
| Baldus, CD | 1 |
| Brandts, CH | 1 |
| Kunzmann, V | 1 |
| Einsele, H | 1 |
| Krämer, A | 1 |
| Schäfer-Eckart, K | 1 |
| Krause, SW | 1 |
| Mackensen, A | 2 |
| Aulitzky, W | 1 |
| Herbst, R | 1 |
| Hänel, M | 1 |
| Kiani, A | 1 |
| Frickhofen, N | 1 |
| Kullmer, J | 1 |
| Kaiser, U | 1 |
| Link, H | 1 |
| Geer, T | 1 |
| Reichle, A | 1 |
| Junghanß, C | 1 |
| Repp, R | 1 |
| Heits, F | 1 |
| Dürk, H | 1 |
| Hase, J | 1 |
| Klut, IM | 1 |
| Illmer, T | 1 |
| Bornhäuser, M | 1 |
| Schaich, M | 1 |
| Parmentier, S | 1 |
| Görner, M | 1 |
| Thiede, C | 1 |
| von Bonin, M | 1 |
| Schetelig, J | 1 |
| Kramer, M | 1 |
| Berdel, WE | 1 |
| Ehninger, G | 1 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Kakisaka, T | 1 |
| Orimo, T | 1 |
| Wakayama, K | 1 |
| Shimada, S | 1 |
| Tsuruga, Y | 1 |
| Kamachi, H | 1 |
| Taketomi, A | 1 |
| Matoba, H | 1 |
| Seta, S | 1 |
| Lei, J | 1 |
| Zhong, J | 1 |
| Hao, J | 1 |
| Liu, Z | 1 |
| Zhang, P | 1 |
| Wu, L | 1 |
| Yan, L | 1 |
| Zhu, J | 1 |
| Zeng, Y | 1 |
| Li, B | 1 |
| Wen, T | 1 |
| Wang, W | 1 |
| Fan, Z | 1 |
| Jiang, Q | 1 |
| Gao, Y | 1 |
| Liu, Q | 1 |
| Liu, XS | 1 |
| Long, H | 1 |
| Huang, YX | 1 |
| Xu, JH | 1 |
| Zhu, JY | 1 |
| DU, QF | 1 |
| Wu, BY | 1 |
| Okada, K | 1 |
| Nakano, Y | 1 |
| Yamasaki, K | 1 |
| Nitani, C | 1 |
| Fujisaki, H | 1 |
| Hara, J | 1 |
| Zu, YL | 1 |
| Zhang, YL | 1 |
| Zhou, J | 1 |
| Han, LJ | 1 |
| Zhao, HF | 1 |
| Gui, RR | 1 |
| Hou, YJ | 1 |
| Song, YP | 1 |
| Rautenberg, C | 1 |
| Nachtkamp, K | 1 |
| Dienst, A | 1 |
| Schmidt, PV | 1 |
| Heyn, C | 1 |
| Kondakci, M | 1 |
| Germing, U | 1 |
| Haas, R | 1 |
| Sid, S | 1 |
| Rey, J | 1 |
| Charbonnier, A | 1 |
| D'Incan, E | 1 |
| Mohty, B | 1 |
| Blaise, D | 1 |
| Vey, N | 1 |
| Domont, J | 1 |
| Massard, C | 1 |
| Lassau, N | 1 |
| Armand, JP | 1 |
| Le Cesne, A | 1 |
| Soria, JC | 1 |
| Cabrera, R | 1 |
| Nelson, DR | 1 |
| Fesler, MJ | 1 |
| Richart, JM | 1 |
| Petruska, PJ | 1 |
| Reardon, DA | 1 |
| Vredenburgh, JJ | 1 |
| Desjardins, A | 1 |
| Peters, K | 1 |
| Gururangan, S | 1 |
| Sampson, JH | 1 |
| Marcello, J | 1 |
| Herndon, JE | 1 |
| McLendon, RE | 1 |
| Janney, D | 1 |
| Friedman, AH | 1 |
| Bigner, DD | 1 |
| Friedman, HS | 1 |
| Pratz, KW | 1 |
| Cho, E | 1 |
| Levis, MJ | 1 |
| Karp, JE | 1 |
| Gore, SD | 1 |
| McDevitt, M | 1 |
| Stine, A | 1 |
| Zhao, M | 1 |
| Baker, SD | 3 |
| Carducci, MA | 1 |
| Wright, JJ | 1 |
| Rudek, MA | 1 |
| Smith, BD | 1 |
| Winkler, J | 1 |
| Rech, D | 1 |
| Kallert, S | 1 |
| Rech, J | 1 |
| Meidenbauer, N | 1 |
| Roesler, W | 1 |
| Saab, S | 1 |
| McTigue, M | 1 |
| Finn, RS | 1 |
| Busuttil, RW | 1 |
| Bernard, P | 1 |
| Charneux, J | 1 |
| Joly, P | 1 |
| Sin, C | 1 |
| Sharma, M | 1 |
| Bayraktar, UD | 1 |
| Chiattone, A | 1 |
| Bashir, Q | 1 |
| Giralt, S | 1 |
| Chen, J | 1 |
| Qazilbash, M | 1 |
| Kebriaei, P | 1 |
| Cortes, J | 2 |
| McCue, D | 1 |
| Kantarjian, H | 2 |
| Champlin, RE | 1 |
| de Lima, M | 1 |
| Inaba, H | 1 |
| Rubnitz, JE | 1 |
| Coustan-Smith, E | 1 |
| Li, L | 1 |
| Furmanski, BD | 1 |
| Mascara, GP | 1 |
| Heym, KM | 1 |
| Christensen, R | 1 |
| Onciu, M | 1 |
| Shurtleff, SA | 1 |
| Pounds, SB | 1 |
| Pui, CH | 1 |
| Ribeiro, RC | 1 |
| Campana, D | 1 |
| Al-Kali, A | 1 |
| Faderl, S | 1 |
| Jones, D | 1 |
| Abril, C | 1 |
| Pierce, S | 1 |
| Brandt, M | 1 |
| Xu, Y | 1 |
| Chenna, V | 1 |
| Hu, C | 1 |
| Sun, HX | 1 |
| Khan, M | 1 |
| Bai, H | 1 |
| Yang, XR | 1 |
| Zhu, QF | 1 |
| Sun, YF | 1 |
| Maitra, A | 1 |
| Fan, J | 1 |
| Anders, RA | 1 |
| Takahara, T | 1 |
| Nitta, H | 1 |
| Hasegawa, Y | 1 |
| Itou, N | 1 |
| Takahashi, M | 1 |
| Wakabayashi, G | 1 |
| Watt, TC | 1 |
| Cooper, T | 1 |
| Ishiko, T | 1 |
| Beppu, T | 1 |
| Chikamoto, A | 1 |
| Tanaka, H | 1 |
| Masuda, T | 1 |
| Okabe, H | 1 |
| Mima, K | 1 |
| Horino, K | 1 |
| Takamori, H | 1 |
| Nakahara, O | 1 |
| Baba, H | 1 |
| Staufer, K | 1 |
| Fischer, L | 1 |
| Seegers, B | 1 |
| Vettorazzi, E | 1 |
| Nashan, B | 1 |
| Sterneck, M | 1 |
| Nadarajah, JT | 1 |
| Collins, M | 1 |
| Raboud, J | 1 |
| Su, D | 1 |
| Rao, K | 1 |
| Loutfy, MR | 1 |
| Walmsley, S | 1 |
| Vitale, A | 1 |
| Boccagni, P | 1 |
| Kertusha, X | 1 |
| Zanus, G | 1 |
| D'Amico, F | 1 |
| Lodo, E | 1 |
| Pastorelli, D | 1 |
| Ramirez Morales, R | 1 |
| Senzolo, M | 1 |
| Burra, P | 1 |
| Cillo, U | 1 |
| Zavaglia, C | 1 |
| Airoldi, A | 1 |
| Mancuso, A | 1 |
| Vangeli, M | 1 |
| Viganò, R | 1 |
| Cordone, G | 1 |
| Gentiluomo, M | 1 |
| Belli, LS | 1 |
| Neuhaus, T | 1 |
| Luyken, J | 1 |
| Navid, F | 1 |
| McCarville, MB | 1 |
| Stewart, CF | 1 |
| Billups, CA | 1 |
| Wu, J | 1 |
| Davidoff, AM | 1 |
| Spunt, SL | 1 |
| Furman, WL | 1 |
| McGregor, LM | 1 |
| Hu, S | 1 |
| Panetta, JC | 1 |
| Turner, D | 1 |
| Fofana, D | 1 |
| Reddick, WE | 1 |
| Leung, W | 1 |
| Santana, VM | 1 |
| Suarez-Pinzon, WL | 1 |
| Mabley, JG | 1 |
| Power, R | 1 |
| Szabó, C | 1 |
| Rabinovitch, A | 1 |
| Diago, T | 1 |
| Pulido, JS | 1 |
| Molina, JR | 1 |
| Collett, LC | 1 |
| Link, TP | 1 |
| Ryan, EH | 1 |
| Kohler, IK | 1 |
| Lorincz, AL | 1 |
| Kitakaze, M | 1 |
| Minamino, T | 1 |
| Node, K | 1 |
| Komamura, K | 1 |
| Shinozaki, Y | 1 |
| Chujo, M | 1 |
| Mori, H | 1 |
| Inoue, M | 1 |
| Hori, M | 1 |
| Kamada, T | 1 |
| Hornschuh, B | 1 |
| Hamm, H | 1 |
| Wever, S | 1 |
| Hashimoto, T | 1 |
| Schröder, U | 1 |
| Bröcker, EB | 1 |
| Zillikens, D | 1 |
| Goon, AT | 1 |
| Tan, SH | 1 |
| Khoo, LS | 1 |
| Tan, T | 1 |
| Loo, WJ | 1 |
| Dean, D | 1 |
| Wojnarowska, F | 1 |
| Pieper, GM | 1 |
| Gross, GJ | 1 |
| Prasad, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas[NCT01338857] | Phase 2 | 12 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Sorafenib ineffective for tx of recurrent or progressive PLGA) | ||
| A Phase II Trial of PS-341 (NSC-681239) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer[NCT00068289] | Phase 2 | 0 participants | Interventional | 2003-09-30 | Completed | ||
| A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer[NCT00182689] | Phase 2 | 89 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)[NCT00828139] | Phase 2 | 189 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age[NCT00893373] | Phase 2 | 276 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial[NCT05404516] | Phase 2 | 88 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | ||
| Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-03-04 | Recruiting | ||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493] | Phase 2 | 32 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Determination of tumor response (CR, PR, SD) will be defined based on the comparison of the baseline MRI performed at study entry to the subsequent MRI which demonstrated best response. PR will be defined by a >15% decrease in tumor volume, as measured by 3D volumetric analysis. (NCT01338857)
Timeframe: MRIs performed after every 3rd 28-day cycle and off-study
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar) | 1 |
To estimate the objective response rates to sorafenib in children and young adults with low-grade astrocytomas, including optic pathway gliomas. (NCT01338857)
Timeframe: one year
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar) | 1 |
Complete Response (CR) is a complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. (NCT00182689)
Timeframe: 8 weeks to 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Platinum-Sensitive | 11 |
| Platinum-Refractory | 2 |
Measured from time of registration to death, or last contact date (NCT00182689)
Timeframe: 0 - 2 years
| Intervention | months (Median) |
|---|---|
| Platinum-Sensitive | 6.7 |
| Platinum-Refractory | 5.3 |
Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. (NCT00182689)
Timeframe: Patients were assessed for adverse events after completion of every 28-day cycle.
| Intervention | Participants with a given type of AE (Number) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AST, SGOT | Allergic reaction/hypersensitivity | Anorexia | Ataxia (incoordination) | Bilirubin (hyperbilirubinemia) | Confusion | Dehydration | Diarrhea | Dizziness | Dyspnea (shortness of breath) | Fatigue (asthenia, lethargy, malaise) | Fever in absence of neutropenia, ANC lt1.0x10e9/L | Hemoglobin | Hypertension | INR (of prothrombin time) | Inf w/normal ANC or Gr 1-2 neutrophils - Skin | Inf w/normal ANC or Gr 1-2 neutrophils - UTI | Lipase | Muscle weakness, not d/t neuropathy - body/general | Nausea | Neuropathy: sensory | PTT (Partial thromboplastin time) | Pain - Abdomen NOS | Pain - Extremity-limb | Pain - Joint | Pain-Other (Specify) | Pancreatitis | Phosphate, serum-low (hypophosphatemia) | Pleural effusion (non-malignant) | Pneumonitis/pulmonary infiltrates | Potassium, serum-low (hypokalemia) | Rash/desquamation | Rash: acne/acneiform | Rash: erythema multiforme | Rash: hand-foot skin reaction | Sodium, serum-low (hyponatremia) | Speech impairment (e.g., dysphasia or aphasia) | Syncope (fainting) | Vomiting | Weight loss | |
| Platinum Refractory | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 8 | 2 | 1 | 0 | 1 | 1 |
| Platinum Sensitive | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 3 | 5 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 9 | 1 | 0 | 1 | 0 | 0 |
Estimated to within at least 15% (95% confidence interval). (NCT00828139)
Timeframe: Weekly, up to 2 years.
| Intervention | months (Median) |
|---|---|
| Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept | 6.0 |
| Platinum Sensitivity Treated With Topotecan Alone | 4.6 |
| Platinum Refractory Treated With Topotecan + Ziv-aflibercept | 4.6 |
| Platinum Refractory Treated With Topotecan Aloine | 4.2 |
"From the date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause.~Progression is defined as 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration." (NCT00828139)
Timeframe: Disease assessments were performed every 6 weeks, up to 2 years.
| Intervention | Months (Median) |
|---|---|
| Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept | 1.8 |
| Platinum Sensitivity Treated With Topotecan Alone | 1.3 |
| Platinum Refractory Treated With Topotecan + Ziv-aflibercept | 1.4 |
| Platinum Refractory Treated With Topotecan Aloine | 1.4 |
"The number of confirmed and unconfirmed complete and partial responses in the subset of patients with measurable disease per RECIST 1.0. Estimated to within at least 17% (95% confidence interval).~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00828139)
Timeframe: Disease assessment for response were performed every 6 weeks, up to 2 years.
| Intervention | proportion of participants (Number) |
|---|---|
| Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept | 0.02 |
| Platinum Sensitivity Treated With Topotecan Alone | 0 |
| Platinum Refractory Treated With Topotecan + Ziv-aflibercept | 0.02 |
| Platinum Refractory Treated With Topotecan Aloine | 0 |
Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. The events listed here are not necessary to be included in Serious Adverse Event. A serious event could be death, life-threatening, hospitalization, disability or permanent damage, congenital anomaly...Grade 3 through 5 adverse event may not meet the criterion of serious adverse event. (NCT00828139)
Timeframe: Toxicity assessment was evaluated after each cycle (21 days), up to 2 years.
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AST, SGOT | Anorexia | Bilirubin (hyperbilirubinemia) | Bronchospasm, wheezing | Calcium, serum-high (hypercalcemia) | Cardiac-ischemia/infarction | Colitis, infectious (e.g., Clostridium difficile) | Confusion | Constipation | Creatinine | Dehydration | Diarrhea | Dizziness | Dyspnea (shortness of breath) | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | GGT (gamma-glutamyl transpeptidase) | Hemoglobin | Hemolysis | Hemorrhage, GI - Upper GI NOS | Hemorrhage, pulmo/upper resp- Bronchopulmonary NOS | Hemorrhage, pulmonary/upper respiratory - Lung | Hemorrhage, pulmonary/upper respiratory - Nose | Hypertension | INR (of prothrombin time) | Inf (clin/microbio) w/Gr 3-4 neuts - Colon | Inf (clin/microbio) w/Gr 3-4 neuts - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Bronchus | Inf w/normal ANC or Gr 1-2 neutrophils - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - UTI | Infection with unknown ANC - Blood | Infection with unknown ANC - Lung (pneumonia) | Left ventricular systolic dysfunction | Leukocytes (total WBC) | Leukoencephalopathy (radiolographic findings) | Lipase | Lymphopenia | Mucositis/stomatitis (clinical exam) - Oral cavity | Muscle weakness, not d/t neuropathy - body/general | Nausea | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Chest wall | Pain - Head/headache | Pain - Pain NOS | Platelets | Pneumonitis/pulmonary infiltrates | Potassium, serum-high (hyperkalemia) | Potassium, serum-low (hypokalemia) | Proteinuria | Psychosis (hallucinations/delusions) | Renal failure | Seizure | Sodium, serum-high (hypernatremia) | Sodium, serum-low (hyponatremia) | Syndromes-Other (Specify) | Thrombosis/thrombus/embolism | Voice changes/dysarthria | Vomiting | Weight loss | |
| Topotecan | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 3 | 0 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 22 | 0 | 0 | 13 | 0 | 1 | 1 | 23 | 0 | 0 | 0 | 0 | 17 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Ziv-aflibercept + Topotecan | 1 | 3 | 1 | 0 | 1 | 1 | 1 | 3 | 0 | 0 | 6 | 1 | 2 | 7 | 15 | 1 | 1 | 9 | 1 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 17 | 1 | 1 | 5 | 1 | 3 | 4 | 30 | 3 | 1 | 2 | 1 | 29 | 0 | 0 | 3 | 1 | 0 | 0 | 1 | 0 | 6 | 1 | 2 | 1 | 2 | 1 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Sorafenib + Temozolomide | 9.4 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug*H/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 45309.7 |
| EIAEDs-Day 28 | 47148.2 |
| Non-EIAEDs-Day 1 | 45238.7 |
| Non-EIAEDs-Day 28 | 128820.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 3397.3 |
| EIAEDs-Day 28 | 3813.9 |
| Non-EIAEDs-Day 1 | 3155.1 |
| Non-EIAEDs-Day 28 | 8118.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | hours (Median) |
|---|---|
| EIAEDs-Day 1 | 8.2 |
| EIAEDs-Day 28 | 2.1 |
| Non-EIAEDs-Day 1 | 24.0 |
| Non-EIAEDs-Day 28 | 4.2 |
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months
| Intervention | participants (Number) |
|---|---|
| Sorafenib + Temozolomide | 19 |
5 reviews available for niacinamide and Recrudescence
| Article | Year |
|---|---|
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The | 2014 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe | 2010 |
[Bullous pemphigoid: a review].
Topics: Aged; Azathioprine; Clobetasol; Combined Modality Therapy; Dapsone; Dose-Response Relationship, Drug | 2011 |
[Pemphigus: a review].
Topics: Adrenal Cortex Hormones; Combined Modality Therapy; Drug Therapy, Combination; Epidermal Growth Fact | 2011 |
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2013 |
12 trials available for niacinamide and Recrudescence
| Article | Year |
|---|---|
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Niacinamide; Oligopeptides; Positron Em | 2019 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; | 2014 |
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular S | 2014 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2015 |
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neopl | 2015 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com | 2015 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com | 2015 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com | 2015 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com | 2015 |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoi | 2017 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; | 2011 |
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2013 |
49 other studies available for niacinamide and Recrudescence
| Article | Year |
|---|---|
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acut | 2022 |
The effects of nicotinamide on reinstatement to cocaine seeking in male and female Sprague Dawley rats.
Topics: Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Cues; Dopamine Uptake Inhibitors; | 2020 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Scree | 2017 |
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free | 2017 |
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
Topics: Antineoplastic Agents; Bone Marrow Cells; CD8 Antigens; Female; Hematopoietic Stem Cell Transplantat | 2018 |
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; fms-Like Tyrosine Kinase 3; | 2018 |
18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.
Topics: Brain; Brain Neoplasms; Fluorine Radioisotopes; Glioblastoma; Humans; Magnetic Resonance Imaging; Ma | 2020 |
Current treatment of myeloproliferative neoplasias: three scenarios.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, | 2020 |
[Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; F | 2013 |
[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The | 2013 |
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Fema | 2014 |
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
Topics: Antineoplastic Agents; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoie | 2014 |
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Disease Models, Animal; Gene Expression | 2014 |
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinas | 2015 |
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Female; fms | 2015 |
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans | 2015 |
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hum | 2015 |
[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectom | 2015 |
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; | 2015 |
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; | 2016 |
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hem | 2016 |
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Co | 2016 |
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Drug Resist | 2016 |
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine K | 2016 |
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoiet | 2017 |
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; | 2010 |
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia | 2010 |
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regul | 2010 |
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host D | 2010 |
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease | 2010 |
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2011 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; | 2011 |
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line | 2012 |
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; | 2011 |
Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Child; Female; Humans; Leukemia, Myeloid, Acut | 2012 |
[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy | 2011 |
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carci | 2012 |
Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy.
Topics: Acrylic Resins; Anti-HIV Agents; Bacterial Infections; Face; Female; HIV-Associated Lipodystrophy Sy | 2012 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver | 2012 |
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
Topics: Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged | 2012 |
Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes.
Topics: Aging; Animals; Apoptosis; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Interferon-gamma; Interleuk | 2003 |
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Dru | 2008 |
Erythema elevatum diutinum treated with niacinamide and tetracycline.
Topics: Drug Therapy, Combination; Erythema; Female; Humans; Middle Aged; Niacinamide; Recurrence; Tetracycl | 1980 |
Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K+c channels.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dogs; Enzyme Activation; | 1996 |
Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cl | 1997 |
Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.
Topics: Aged; Anti-Bacterial Agents; Complement C3; Diarrhea; Doxycycline; Drug Combinations; Female; Fluore | 2000 |
A severe persistent case of recurrent pemphigoid gestationis successfully treated with minocycline and nicotinamide.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Immunosuppressive Agents; Minocycline; Niacinamide; Pe | 2001 |
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Disease; Dogs; | 1987 |
Recurrent aphthous ulcers.
Topics: Chronic Disease; Humans; Niacinamide; Recurrence; Stomatitis, Aphthous | 1972 |